MedTrace Logo

Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI

NCT03958422 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-05-22

No results posted yet for this study

Summary

In this study, advanced techniques of myocardial nuclear magnetic perfusion scanning were used to quantitatively assess infarct size after acute myocardial infarction, saved viable myocardium, and microcirculatory obstruction area. Objectively and quantitatively evaluate early use of cardiomyopeptidin for direct PCI of ST-segment elevation myocardial infarction. After the improvement of microcirculation and increase the intervention effect of viable myocardium.

Conditions

  • Survival Myocardial Area After Acute Myocardial Death
  • Left Ventricular Ejection Fraction

Interventions

DRUG

cardiomyopeptidin

The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.

Sponsors & Collaborators

  • Dalian Zhen-Ao Bio-Tech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yundai Chen · cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2019-11-30
Completion
2020-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03958422 on ClinicalTrials.gov